AI Article Synopsis
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple body systems and presents with a wide range of symptoms.
- Recent research has provided new information on the causes, biomarkers, and clinical features of SLE, leading to potential advancements in treatment options.
- The review aims to summarize the key findings related to SLE that emerged in 2021, building upon previous annual reviews.
Article Abstract
Systemic lupus erythematosus (SLE) is a chronic multisystem auto-immune disease with extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE about pathogenetic pathways, biomarkers, and data on clinical manifestations are progressively emerging, and new drugs and new therapeutic strategies have been proposed to improve the control of disease activity. Thus, this review is aimed to summarise the most relevant data about SLE emerged during 2021, following the previous annual review of this series.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.55563/clinexprheumatol/nolysy | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune complexes-mediated activation of neutrophils in systemic lupus erythematosus is dependent on RNA recognition by toll-like receptor 8.
Front Immunol
December 2024
Division of Rheumatology, University of Washington, Seattle, WA, United States.
Introduction: Neutrophil activation is important in systemic lupus erythematosus (SLE). We previously demonstrated that ribonucleoprotein (RNP) immune complexes (ICs) promoted neutrophil activation in a TLR7/8-dependent manner. However, it remains unclear if this mechanism occurs in patients.
View Article and Find Full Text PDFLupus Nephritis and Chronic Kidney Disease: A Scoping Review.
Nephrology (Carlton)
January 2025
Division of Nephrology, School of Clinical Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR.
Prevention of end-stage kidney disease (ESKD) is a major objective in the management of patients with lupus nephritis (LN). Chronic kidney disease (CKD) of variable severity is common in these patients, but recent literature has mostly focused on novel immunosuppressive treatments for acute LN, while the data on CKD is relatively limited. This scoping review aims to summarise available data on the prevalence and risk factors for CKD in patients with LN.
View Article and Find Full Text PDFReal-World Prevalence, Incidence and Management of Systemic Lupus Erythematosus in Germany: A Retrospective Claims Data Analysis.
Rheumatol Ther
January 2025
Amgen GmbH, Munich, Germany.
Introduction: This study evaluated the prevalence and incidence of systemic lupus erythematosus (SLE) in Germany and explored real-world data on sequence of therapy (SOT; sequence of drugs as prescribed in clinical practice).
Methods: This retrospective, observational, longitudinal cohort study using German claims data from the WIG2 GmbH Scientific Institute for Health Economics and Health System Research database (January 2011-December 2019), extrapolated to the statutory health insurance (SHI)-insured population, evaluated prevalence and incidence in an epidemiological analysis group and SLE treatment patterns in an incident cohort (subgroup ≥ 18 years of age with incident disease and ≥ 24-month follow-up post index date). Analyses were descriptive.
Zinc oxide nanoparticles decorated nitrogen doped porous reduced graphene oxide-based hybrid to sensitive detection of hydroxychloroquine in plasma and urine.
J Mater Sci Mater Med
January 2025
Department of Chemistry, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
The antimalarial hydroxychloroquine (HCQ) has considered for the treatment of systemic lupus erythematosus. Moreover, HCQ has been used as a drug to treat Coronavirus disease (COVID-19). In this work, nitrogen doped porous reduced graphene oxide (NprGO) has been prepared via environmentally friendly process using Fummaria Parviflora extract.
View Article and Find Full Text PDFSystemic lupus erythematosus is associated with an increased risk of cervical artery dissection.
Sci Rep
January 2025
New York Medical Group, EC Healthcare, Kowloon, Hong Kong.
Limited evidence suggests that autoimmune diseases are associated with an increased risk of cervical artery dissection (CeAD). We hypothesized individuals with systemic lupus erythematosus (SLE) would have an increased risk of CeAD following SLE diagnosis compared to matched non-lupus controls. We queried a de-identified United States electronic medical records network (TriNetX, Inc.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!